Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Novartis signs $3.2bn drug delivery deal with Alteogen

The agreement includes option exercise fees, milestone payments, and royalties on net sales of products commercialised with ALT-B4 technology.

Latest news

Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn

The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential.

GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal

HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue.

FDA cracks down on online black market for weight loss peptides

The agency’s latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

Typewriter raises $56m Series A to progress non-viral gene therapy platform

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.

Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule

The deal includes an upfront payment to Biocytogen, along with eligibility for milestone payments tied to specified objectives.